# US 2015/0031682 A1 · Anti-malarial agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0031682 A1
- Document ID: US20150031682A1
- Status: Published application
- Kind: A1
- Application number: 14/379,332
- Filed: 2013-02-15
- Published: 2015-01-29
- Earliest claimed: 2012-02-17
- Assignees: Mmv Medicines for Malaria Venture; University of Cape Town
- Applicants: University of Cape Town; Mmv Medicines for Malaria Venture
- Inventors: Yassir Younis; Kelly Chibale; Michael John Witty; David Waterson
- Web page: https://patentgrep.com/patent/US20150031682A1

## CPC

- C07D 241/20: Nitrogen atoms (nitro radicals C07D241/16)
- A61K 31/4965: Non-condensed pyrazines
- A61K 31/497: containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 33/00: Antiparasitic agents
- A61P 33/06: Antimalarials
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 401/14: containing three or more hetero rings
- C07D 403/10: linked by a carbon chain containing aromatic rings
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention is related to a use of aminopyrazine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyrazine derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.

## Claims

### Claim at position 1

1-27. (canceled)

### Claim 28

An aminopyrazine according to Formula (I),
wherein X is CR1 or N; Y is selected from CF3, —C(O)—NR3R4; O—R6; SO2—R6; R1 is selected from H and halogen; R2 is selected from SO2—R5 and —C(O)—R10; R3 and R4 are independently selected from H and optionally substituted C1-C6 alkyl; R5 is selected from —NR7R8 and R9; R6 is optionally substituted C1-C6 alkyl; R7 and R8 are independently selected from H and optionally substituted C1-C6 alkyl; R9 is optionally substituted C1-C6 alkyl or optionally substituted C3-C8 alkyl; R10 is —NR11R12; R11 and R12 are independently selected from H and optionally substituted C1-C6 alkyl or NR11R12 form together an optionally substituted heterocycloalkyl; as well as pharmaceutically acceptable salts, complexes, hydrates, solvates, or polymorphs, tautomers, geometrical isomers, optically active forms and pharmaceutically active derivative thereof.

### Claim 29 (depends on 28)

The aminopyrazine according to claim 28, wherein X is N.

### Claim 30 (depends on 28)

The aminopyrazine according to claim 28, wherein X is CR1.

### Claim 31 (depends on 28)

The aminopyrazine according to claim 28, wherein Y is CF3.

### Claim 32 (depends on 28)

The aminopyrazine according to claim 28, wherein Y is —C(O)—NHR3.

### Claim 33 (depends on 28)

The aminopyrazine according to claim 28, wherein Y is SO2—R6.

### Claim 34 (depends on 28)

The aminopyrazine according to claim 28, wherein R2 is SO2—R5.

### Claim 35 (depends on 28)

The aminopyrazine according to claim 28, wherein R2 is SO2—R9.

### Claim 36 (depends on 28)

The aminopyrazine according to claim 28, wherein R2 is SO2—R9 and R9 is optionally substituted C1-C6 alkyl.

### Claim 37 (depends on 28)

The aminopyrazine according to claim 28, wherein R2 is —C(O)—R10.

### Claim 38 (depends on 37)

The aminopyrazine according to claim 37, wherein NR11R12 form together an optionally substituted heterocycloalkyl.

### Claim 39 (depends on 37)

The aminopyrazine according to claim 37, wherein R11 and R12 are independently selected from H and optionally substituted C1-C6 alkyl.

### Claim 40 (depends on 28)

The aminopyrazine according to claim 28, wherein the aminopyrazine is selected from the following group:
3-(6-methoxypyridin-3-yl)-5-(4-(methylsulfonyl)phenyl)pyrazin-2-amine;
5-(4-(methylsulfonyl)phenyl)-3-(4-(trifluoromethyl)phenyl)pyrazin-2-amine;
5-(4-(methylsulfonyl)phenyl)-3-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-amine;
4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)benzamide;
4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)benzamide;
(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(4-methylpiperazin-1-yl)methanone;
(4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(4-methyl piperazin-1-yl)methanone;
(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(piperazin-1-yl) methanone;
(4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(piperazin-1-yl) methanone;
(4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(morpholino)methanone;
(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(morpholino)methanone;
(4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(4-methyl-1,4-diazepan-1-yl)methanone;
4-(5-amino-6-(3-fluoro-4-(trifluoromethyl)phenyl)pyrazin-2-yl)benzamide;
4-(5-amino-6-(4-(methylsulfonyl)phenyl)pyrazin-2-yl)benzamide;
4,4′-(3-aminopyrazine-2,6-diyl)dibenzamide;
4-(3-amino-6-(4-carbamoylphenyl)pyrazin-2-yl)-N-methylbenzamide;
4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)-N-methylbenzene sulfonamide;
5-(4-(ethyl sulfonyl)phenyl)-3-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-amine;
5-(4-(isopropylsulfonyl)phenyl)-3-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-amine;
(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(4-(tert-butyl) piperazin-1-yl)methanone;
(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(3-hydroxypyrrolidin-1-yl)methanone;
(4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(4-hydroxy piperidin-1-yl)methanone;
(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(4-hydroxy piperidin-1-yl)methanone;
(4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(4-(tert-butyl)piperazin-1-yl)methanone;
(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(4-methyl-1,4-diazepan-1-yl)methanone;
(4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(1,4-diazepan-1-yl)methanone;
(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(1,4-diazepan-1-yl)methanone;
(4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(3-amino pyrrolidin-1-yl)methanone;
(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(3-amino pyrrolidin-1-yl)methanone;
(4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(3-hydroxy pyrrolidin-1-yl)methanone;
(4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(4-amino cyclohexyl)methanone;
(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)phenyl)(4-amino cyclohexyl) methanone;
5-(4-(cyclopropylmethylsulfonyl)phenyl)-3-(6-(trifluoromethyl)pyridin-3-yl) pyrazin-2-amine; and
5-(4-(cyclopropylsulfonyl)phenyl)-3-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-amine;
as well as pharmaceutically acceptable salts, complexes, hydrates, solvates, or polymorphs, tautomers, geometrical isomers, optically active forms and pharmaceutically active derivative thereof.

### Claim 41 (depends on 28)

A pharmaceutical formulation containing at least one aminopyrazine according to claim 28 and a pharmaceutically acceptable carrier, diluent or excipient thereof.

### Claim 42 (depends on 41)

The pharmaceutical formulation according to claim 41 further comprising an antimalarial agent.

### Claim 43 (depends on 28)

A method for preventing or treating malaria in a patient, wherein the method comprises administering an effective amount of an aminopyrazine according to claim 28 in a patient in need thereof.

### Claim 44 (depends on 43)

The method according to claim 43, wherein the aminopyrazine is to be administered in combination with a co-agent useful in the treatment of malaria.

### Claim 45 (depends on 28)

A process for the preparation of an aminopyrazine derivative according to Formula (I) comprising the step of reacting a intermediate of Formula (v) with a boronic acid of Formula (vi) under Suzuki reaction conditions to lead to a compound of Formula (I):
wherein X, Y and R1 are as defined in claim 28 and A is
and D is:

### Claim 46 (depends on 28)

An intermediate of Formula (v) wherein A is:
wherein X and Y are as defined in claim 28.

### Claim 47 (depends on 45)

A process for the preparation of an aminopyrazine derivative according to Formula (I) comprising the step of reacting a derivative according to Formula (viii) with a boronic acid of Formula (iv) under Suzuki reaction conditions to lead to a compound of Formula (I):
wherein A, D, X, Y and R1 are as defined in claim 45.

### Claim 48 (depends on 28)

An intermediate of formula (viii) wherein D is
and R2 is as defined in claim 28.

### Claim 49 (depends on 45)

A process for the preparation of an aminopyrazine derivative according to Formula (I) comprising the step of reacting a derivative according to Formula (xix) in TFA to lead to lead to a compound of Formula (V):
wherein A, X, Y and R1 are as defined in claim 45.

### Claim 50

An intermediate of formula (xix) wherein the intermediate is selected from the following group: tert-butyl 4-(4-(5-amino-6-(4-(trifluoromethyl)phenyl)pyrazin-2-yl)benzoyl)piperazine-1-carboxylate and tert-butyl 4-(4-(5-amino-6-(6-(trifluoromethyl) pyridin-3-yl)pyrazin-2-yl)benzoyl) piperazine-1-carboxylate.
